G-BA decisions 15 February 2024
Here are the G-BA decisions from the G-BA meeting held on 15 February 2024 on the early benefit assessments of Trodelvy, Lonsurf,
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Here are the G-BA decisions from the G-BA meeting held on 15 February 2024 on the early benefit assessments of Trodelvy, Lonsurf,
Most medicines are reimbursed at 100% from the day of launch in Germany, i.e. coverage by SHI funds is granted with the marketing authorization
On 16 June 2022, the G-BA published its findings on the benefit assessments of Gavreto (pralsetinib) and Abecma (idecabtagen vicleucel). Both drugs
Here is my last blog post of the year. Somehow we’ve come to the end of another year. Most of us are